51 results about "Pterin" patented technology

Disclosed herein are analogs of tetrahydrobiopterin, compositions containing the same, and methods of treating an individual suffering from a condition responsive to tetrahydrobiopterin by administration of the analog. These analogs are contemplated for use wherever tetrahydrobiopterin is currently used to treat conditions responsive to tetrahydrobiopterin therapies.

Ricin A-chain is an N-glycosidase that attacks ribosomal RNA at a highly conserved adenine residue. Crystallographic studies show that not only adenine and formycin, but also pterin-based rings can bind in the ricin active site. For a better understanding of the recognition mode between ricin, and adenine-like rings, the interaction energies and geometries were calculated for a number of complexes. Shiga toxin, a compound essentially identical to the protein originally isolated from Shigella dysenteriae, has an active protein chain that is a homologue of the ricin active chain, and catalyzes the same depurination reaction. The present invention is drawn to identifying inhibitors of ricin and Shiga toxin, using methods molecular mechanics and ab initio methods and using the identified inhibitors as antidotes to ricin or Shiga toxin, or to facilitate immunotoxin treatment by controlling non-specific cytotoxicity.

The present invention provides a transformed cell which is transformed by at least one gene of enzymes participating in biosynthesis of tetrahydrobiopterin and a process for the production of a biopterin compound using the same. In accordance with the present invention, the biopterin compound can be produced in large quantities in an industrial advantageous manner from less expensive materials.

The present invention relates to stable pharmaceutical compositions of tetrahydrobiopterin and processes for producing such compositions. Particularly the present invention relates to stable pharmaceutical compositions comprising tetrahydrobiopterin and at least one stabilizing agent.

Disclosed are crystalline forms of sepiapterin free base selected from polymorphs A, B, C, D, E, F, and G, and combinations thereof, as well as crystalline polymorphs of salts of sepiapterin. Also disclosed are pharmaceutical compositions containing one or more such polymorphs and methods for preparing such polymorphs. Sepiapterin is useful in the treatment of a number diseases associated with low cellular levels of BH4, for example, phenylketonuria.

The present invention relates to new pharmaceutical salts and / or co-crystals of sepiapterin which exhibit improved properties. In particular, the invention relates to salts of sepiapterin with improved stability. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts and / or co-crystals of sepiapterin, as well as methods of treating tetrahydrobiopterin-related disorders including administration of a sepiapterin salt and / or co-crystal of the invention to a subject in need thereof.

The invention relates to process for in vitro prediction of a potentially allergenic substance wherein monocytes and / or macrophages and / or myelomonocytic cell lines are cultivated in the presence of the substance and interferon-γ, whereby productions of cytokines and / or neopterin are increased and measured. The allergic reaction may be estimated by measuring up regulated or down-regulated genes chosen from G1P2, OASL, IFIT1, TRIM22, IFI44L, MXI, RSAD2, IFIT3, IFITM1, IFIT2, C 33.28 HERV-H protein mRNA, IFITM3, XK, GPR15, MT1G, MT1B; MT1A, ADFP, IL8, MT1E, MT1F, MT1H, SLC30A1, SERPINB2, CD83, TncRNA or expression products from them are measured. The invention also relates to a reagent kit for use in the process comprising interferon-γ and reagents which recognise cytokines preferably each of IL-8 and neopterin and / or reagents such as probes recognising up-regulated or down-regulated genes.

Disclosed herein are analogs of tetrahydrobiopterin, compositions containing the same, and methods of treating an individual suffering from a condition responsive to tetrahydrobiopterin by administration of the analog. These analogs are contemplated for use wherever tetrahydrobiopterin is currently used to treat conditions responsive to tetrahydrobiopterin therapies.

The present invention relates to substituted pterin compounds, their synthesis and use. In particular, the present invention relates to a new precursor compound and its analogs for synthesizing a new substituted pterin compound and its analogs. These new compounds are particularly suitable for treating molybdenum cofactor deficiency.

The present invention relates to a biomarker and a method for determining an oxidative stress level in a biological sample, which employs co-factor-dependent oxidative stress parameters, as well as a kit adapted for carrying out such a method. In one aspect the co-factor is tetrahydrobiopterin.

The invention discloses a body fluid pterin spectrum detection kit and its use. The kit includes pterin mixed standards and creatinine.

The invention relates to a metabolic marker of medulloblastoma in urine and an application thereof. Specifically, the invention relates to an application of a reagent in preparing kits and / or chips for diagnosis and / or prognostic of medulloblastoma for detecting metabolites levels in urine of a subject. Metabolites are selected from one or more of the following matters: Uropterin, 20-oxo-leukotriene E4, Cortolone, Tetrahydrocortisone, [6]-Gingerdiol 3,5-diacetate, Pteroside Z, 12-oxo-2,3-dinor-10,15-phytodienoic acid, Melleolide M, Ethyl 7-epi-12-hydroxyjasmonate glucoside, Piperdial, Epishyobunone, 4R,5S,7R,11S)-11,12-Dihydroxy-1(10)-spirovetiven-2-one11-glucoside, PC-M5 and Acuminoside.

The invention relates to a preparation method of L-erythrotype biopterin compounds. Wherein, the L-erythrotype biopterin compound has the structure shown in formula (I), and the L-erythrotype biopterin compound shown in formula (I) is mainly represented by formula (II) or formula (III) The compound with the structure shown is prepared through a dihydroxylation reaction; the preparation method of the L-erythro-type biopterin compound has high production efficiency, low cost, and is green and environmentally friendly, and is suitable for industrial production.

A method of treating, preventing, reversing, or ameliorating diastolic dysfunction includes reducing S-glutathionylated myosin binding protein-C (MyBP-C) level by administering to a host in need thereof a therapeutically effective amount of tetrahydrobiopterin (BH4).

The present invention relates to substituted pterin compounds, their synthesis and use. In particular, the present invention relates to a new precursor compound and its analogs for synthesizing a new substituted pterin compound and its analogs. These new compounds are particularly suitable for treating molybdenum cofactor deficiency.

The invention discloses a recombinant escherichia coli producing melatonin, a construction method and application thereof. The present invention firstly discloses recombinant Escherichia coli, compared with the recipient Escherichia coli, the expression level of the gene related to melatonin biosynthesis is increased and / or the content of the melatonin biosynthesis-related protein is increased and / or the The activity of the melatonin biosynthesis-related protein is increased; the melatonin is selected from at least one of the following: phenylalanine hydroxylase, dihydromonophosphate reductase, 4a-hydroxytetrahydrobiopterin dehydratase, Aspartate transaminase family proteins, N‑acetyltransferase and caffeic acid‑O‑methyltransferase. The construction method and application of the recombinant Escherichia coli are further disclosed. The melatonin-producing recombinant Escherichia coli strain of the invention has significantly higher melatonin synthesis efficiency than other existing strains, and is of great significance to the industrialized production and large-scale application of melatonin.